LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) — Shahneen Sandhu (2020) | RDL Network
LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
Zhen Shi, Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Marie-Laurence Harle-Yge, Małgorzata Nowicka, Matthew Wongchenko, Johann S. de Bono
Cora N. Sternberg, Sergio Bracarda, Johann S. de Bono, Christopher J. Sweeney, K.N. Chi, David Olmos, Shahneen Sandhu, Christophe Massard, Josep Garcia, Fanny Schenkel, G. Chen, Adam Harris, Heather Hinton, Nobuaki Matsubara
Nobuaki Matsubara, Johann S. de Bono, Christopher Sweeney, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Josep Garcia, Geng Chen, Adam Harris, Fanny Schenkel, Rucha Sane, Healther Hinton, Sergio Bracarda, Cora N. Sternberg
Johann S. de Bono, Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Josep Garcia, Małgorzata Nowicka, Matthew Wongchenko, Zhen Shi
Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, B. Yа. Alekseev, Francis Parnis, Vagif Atduev, Gary L. Buchschacher, Rustem Gafanov, Luis Corrales, Michael Borre, Daniil Stroyakovskiy, Gustavo Vasconcelos Alves, Evangelos Bournakis, Javier Puente, Marie-Laurence Harle-Yge, Jorge D. Gallo,
Discussion(0)
No comments yet. Be the first to comment.